Original Article

You have full text access to this OnlineOpen article

“A la carte” treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding

  1. Christophe Bureau M.D.1,2,*,
  2. Jean-Marie Péron1,2,
  3. Laurent Alric1,
  4. Joséphine Morales1,
  5. Jérǒme Sanchez1,
  6. Karl Barange1,
  7. Jean-Louis Payen1,
  8. Jean-Pierre Vinel1,2

Article first published online: 7 MAR 2007

DOI: 10.1002/hep.1840360611

Issue

Hepatology

Hepatology

Volume 36, Issue 6, pages 1361–1366, December 2002

Additional Information

How to Cite

Bureau, C., Péron, J.-M., Alric, L., Morales, J., Sanchez, J., Barange, K., Payen, J.-L. and Vinel, J.-P. (2002), “A la carte” treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology, 36: 1361–1366. doi: 10.1002/hep.1840360611

Author Information

  1. 1

    Service d'Hépato-Gastro-Enterologie, Fédération Digestive Purpan, CHU Toulouse, France

  2. 2

    INSERM, U531, CHU Rangueil, Toulouse, France

*Federation Digestive CHU Purpan, Place du Dr Baylac, Toulouse, 31059, France. fax: (33) 561 779 015

Publication History

  1. Issue published online: 7 MAR 2007
  2. Article first published online: 7 MAR 2007
  3. Manuscript Accepted: 2 SEP 2002
  4. Manuscript Received: 7 MAR 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (618K)

Reference

  • 1
    Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D. β-Adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991; 324: 1532–1538.
  • 2
    Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. β-Adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25: 63–70.
    Direct Link:
  • 3
    Viallet A, Marleau D, Huet M, Martin F, Farley A, Villeneuve JP, Lavoie P. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975; 69: 1297–1300.
  • 4
    Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 1401–1407.
  • 5
    Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056–1059.
  • 6
    Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624–1629.
  • 7
    Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variccal bleeding in cirrhosis. Hepatology 2000; 32: 930–934.
    Direct Link:
  • 8
    Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodes J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990; 11: 230–238.
    Direct Link:
  • 9
    Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114: 869–873.
  • 10
    Grace ND, Groszmann RJ, Garcia-Tsao G, Burroughs AK, Pagliaro L, Makuch RW, Bosch J, et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 1998; 28: 868–880.
    Direct Link:
  • 11
    Vinel JP, Schuller P, Hervieu C, Cales P, Cassigneul J, Pascal JP. Outcome of patients after obliteration of esophageal varices by endoscopic sclerosis. Results of a prospective study. Gastroenterol Clin Biol 1986; 10: 584–588.
  • 12
    Vinel JP, Monnin JL, Combis JM, Cales P, Desmorat H, Pascal JP. Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis. Hepatology 1990; 11: 239–242.
    Direct Link:
  • 13
    Cales P, Grasset D, Ravaud A, Meskens C, Blanc M, Vinel JP, Cotonat J, et al. Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol 1989; 27: 763–770.
  • 14
    Castaneda B, Morales J, Lionetti R, Moitinho E, Andreu V, Perez-Del-Pulgar S, Pizcueta P, et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 2001; 33: 821–825.
    Direct Link:
  • 15
    Valla D, Jiron MI, Poynard T, Braillon A, Lebrec D. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987; 5: 144–148.
  • 16
    McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK. Clinical vs. haemodynamic response to drugs in portal hypertension. J Hepatol 1998; 28: 1015–1019.
  • 17
    Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, Morse SS, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6: 101–106.
    Direct Link:
  • 18
    Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 334: 647–655.
  • 19
    Angelico M, Carli L, Piat C, Gentile S, Capocaccia I. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology 1997; 113: 1632–1639.
  • 20
    Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, Tanno H, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993; 18: 477–484.
    Direct Link:
  • 21
    Groszmann RJ. β-Adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology 1997; 113: 1794–1797.
  • 22
    Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 111: 701–709.
  • 23
    Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982; 83: 338–340.
  • 24
    Haag K, Rossle M, Ochs A, Huber M, Siegerstetter V, Olschewski M, Berger E, et al. Correlation of duplex sonography findings and portal pressure in 375 patients with portal hypertension. AJR Am J Roentgenol 1999; 172: 631–635.
  • 25
    Bosch J, Bordas JM, Rigau J, Viola C, Mastai R, Kravetz D, Navasa M, et al. Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: comparison with measurements by variceal puncture in patients undergcing endoscopic sclerotherapy. Hepatology 1986; 6: 667–672.
    Direct Link:
  • 26
    Escorsell A, Bordas JM, Castaneda B, Llach J, Garcia-Pagan JC, Rodes J, Bosch J. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 1061–1067.
    Direct Link:
Get PDF (618K)